Zhang Wujie, Zhao Shuting, Rao Wei, Snyder Jedidiah, Choi Jung K, Wang Jifu, Khan Iftheker A, Saleh Navid B, Mohler Peter J, Yu Jianhua, Hund Thomas J, Tang Chuanbing, He Xiaoming
Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA ; Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH 43210, USA ; Biomolecular Engineering Program, Department of Physics and Chemistry, Milwaukee School of Engineering, Milwaukee, WI 53202, USA.
J Mater Chem B. 2013;2013(7):1002-1009. doi: 10.1039/C2TB00058J. Epub 2012 Nov 23.
In this study, we report the preparation of a novel microcapsule of ~ 100 μm with a liquid (as compared to solid-like alginate hydrogel) core and an alginate-chitosan-alginate (ACA) shell for encapsulation and culture of embryonic stem (ES) cells in the miniaturized 3D space of the liquid core. Murine R1 ES cells cultured in the microcapsules were found to survive (> 90%) well and proliferate to form either a single aggregate of pluripotent cells or embryoid body (EB) of more differentiated cells in each microcapsule within 7 days, dependent on the culture medium used. This novel microcapsule technology allows massive production of the cell aggregates or EBs of uniform size and controllable pluripotency, which is important for the practical application of stem cell based therapy. Moreover, the semipermeable ACA shell was found to significantly reduce immunoglobulin G (IgG) binding to the encapsulated cells by up to 8.2 times, compared to non-encapsulated cardiac fibroblasts, mesenchymal stem cells, and ES cells. This reduction should minimize inflammatory and immune responses induced damage to the cells implanted becasue IgG binding is an important first step of the undesired host responses. Therefore, the ACA microcapsule with selective shell permeability should be of importance to advance the emerging cell-based medicine.
在本研究中,我们报道了一种新型微胶囊的制备,其直径约为100μm,具有液体(与类固体海藻酸盐水凝胶相比)核心以及海藻酸-壳聚糖-海藻酸(ACA)外壳,用于在液体核心的微型三维空间中封装和培养胚胎干细胞(ES细胞)。发现在微胶囊中培养的小鼠R1 ES细胞存活良好(> 90%),并在7天内在每个微胶囊中增殖形成多能细胞的单个聚集体或更分化细胞的胚状体(EB),这取决于所使用的培养基。这种新型微胶囊技术能够大量生产尺寸均匀且多能性可控的细胞聚集体或EB,这对于基于干细胞的治疗的实际应用非常重要。此外,与未封装的心脏成纤维细胞、间充质干细胞和ES细胞相比,发现半透性的ACA外壳可使免疫球蛋白G(IgG)与封装细胞的结合显著减少高达8.2倍。这种减少应能将因IgG结合(这是不期望的宿主反应的重要第一步)引起的对植入细胞的炎症和免疫反应损伤降至最低。因此,具有选择性外壳渗透性的ACA微胶囊对于推动新兴的细胞医学具有重要意义。